AnaptysBio (ANAB) News Today $14.55 -0.45 (-3.00%) (As of 12/20/2024 05:23 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Franklin Resources Inc. Has $12.31 Million Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)Franklin Resources Inc. decreased its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 23.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 354,370 shares of the bioDecember 21 at 4:46 AM | marketbeat.comTruist Financial Cuts AnaptysBio (NASDAQ:ANAB) Price Target to $20.00December 21 at 2:53 AM | americanbankingnews.comAnaptysBio price target lowered to $36 from $66 at JPMorganDecember 20 at 3:24 AM | markets.businessinsider.comAnaptysBio (NASDAQ:ANAB) Given New $36.00 Price Target at JPMorgan Chase & Co.JPMorgan Chase & Co. reduced their price target on AnaptysBio from $66.00 to $36.00 and set an "overweight" rating for the company in a report on Thursday.December 19 at 12:32 PM | marketbeat.comAnaptysBio: Doubts About Cash And Upcoming Rheumatoid Arthritis ReadoutDecember 18 at 7:02 PM | seekingalpha.comDeep Dive Into AnaptysBio Stock: Analyst Perspectives (9 Ratings)December 18 at 7:02 PM | benzinga.comAnaptysBio (NASDAQ:ANAB) Shares Gap Up - Here's What HappenedAnaptysBio (NASDAQ:ANAB) Shares Gap Up - Still a Buy?December 18 at 5:12 PM | marketbeat.comTruist Financial Lowers AnaptysBio (NASDAQ:ANAB) Price Target to $20.00Truist Financial lowered their price target on AnaptysBio from $30.00 to $20.00 and set a "hold" rating on the stock in a report on Wednesday.December 18 at 12:27 PM | marketbeat.comStifel Nicolaus Sticks to Their Buy Rating for AnaptysBio (ANAB)December 17, 2024 | markets.businessinsider.comWedbush Has Negative Outlook for AnaptysBio FY2024 EarningsDecember 17, 2024 | americanbankingnews.comAnaptysBio (NASDAQ:ANAB) Shares Up 9.1% - Here's What HappenedAnaptysBio (NASDAQ:ANAB) Shares Up 9.1% - Time to Buy?December 16, 2024 | marketbeat.comAnaptysBio, Inc. (NASDAQ:ANAB) Sees Significant Growth in Short InterestAnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) saw a large increase in short interest in November. As of November 30th, there was short interest totalling 7,100,000 shares, an increase of 5.8% from the November 15th total of 6,710,000 shares. Based on an average daily trading volume, of 447,100 shares, the days-to-cover ratio is presently 15.9 days. Currently, 27.3% of the company's stock are short sold.December 16, 2024 | marketbeat.comHC Wainwright Increases Earnings Estimates for AnaptysBioDecember 16, 2024 | americanbankingnews.comAnaptysBio FY2024 EPS Estimate Increased by HC WainwrightAnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Analysts at HC Wainwright upped their FY2024 earnings per share estimates for shares of AnaptysBio in a research report issued on Wednesday, December 11th. HC Wainwright analyst E. Bodnar now forecasts that the biotechnology company will earn ($6.09)December 16, 2024 | marketbeat.comWhat is Wedbush's Estimate for AnaptysBio FY2024 Earnings?AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Investment analysts at Wedbush reduced their FY2024 earnings per share (EPS) estimates for shares of AnaptysBio in a note issued to investors on Wednesday, December 11th. Wedbush analyst D. Nierengarten now expects that the biotechnology company willDecember 16, 2024 | marketbeat.comBrokerages Set AnaptysBio, Inc. (NASDAQ:ANAB) Target Price at $51.45December 15, 2024 | americanbankingnews.comQ1 Earnings Forecast for AnaptysBio Issued By HC WainwrightDecember 15, 2024 | americanbankingnews.comGuggenheim Issues Pessimistic Forecast for AnaptysBio (NASDAQ:ANAB) Stock PriceDecember 14, 2024 | americanbankingnews.comAnaptysBio's (ANAB) "Outperform" Rating Reiterated at WedbushDecember 14, 2024 | americanbankingnews.comWells Fargo & Company Cuts AnaptysBio (NASDAQ:ANAB) Price Target to $40.00December 14, 2024 | americanbankingnews.comWhat is HC Wainwright's Forecast for AnaptysBio Q1 Earnings?AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for AnaptysBio in a report issued on Wednesday, December 11th. HC Wainwright analyst E. Bodnar forecasts that the biotechnology company will post earnings of ($1.44) per sharDecember 13, 2024 | marketbeat.comHC Wainwright Downgrades AnaptysBio (NASDAQ:ANAB) to NeutralDecember 13, 2024 | americanbankingnews.comAnaptysBio price target lowered to $40 from $56 at Wells FargoDecember 13, 2024 | markets.businessinsider.comAnaptysBio price target lowered to $36 from $90 at GuggenheimDecember 13, 2024 | markets.businessinsider.comBuy Rating on AnaptysBio: Strategic Focus on Rosnilimab Amidst Stock Valuation OpportunityDecember 12, 2024 | markets.businessinsider.comHC Wainwright & Co. Downgrades AnaptysBio (ANAB)December 12, 2024 | msn.comAnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Rating of "Moderate Buy" from AnalystsAnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twelve analysts that are covering the company, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and eight have assigned a bDecember 12, 2024 | marketbeat.comAnaptysBio to Drop Eczema Drug Candidate After Trials Miss Endpoints; Shares FallDecember 11, 2024 | marketwatch.comAnaptysBio (ANAB) Receives a Buy from TD CowenDecember 11, 2024 | markets.businessinsider.comAnaptysBio to abandon eczema drug development after mid-stage trial failureDecember 11, 2024 | reuters.comAnaptysBio abandons eczema drug development after mid-stage trial failureDecember 11, 2024 | reuters.comAnaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic DermatitisDecember 11, 2024 | globenewswire.comFrazier Life Sciences Management L.P. Purchases 43,598 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)Frazier Life Sciences Management L.P. boosted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 2.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,209,189 shares of the biotechDecember 10, 2024 | marketbeat.comPoint72 Asset Management L.P. Increases Stake in AnaptysBio, Inc. (NASDAQ:ANAB)Point72 Asset Management L.P. raised its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 202.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 54,200 shares of the biotechnologDecember 10, 2024 | marketbeat.comVerition Fund Management LLC Acquires Shares of 22,036 AnaptysBio, Inc. (NASDAQ:ANAB)Verition Fund Management LLC bought a new position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 22,036 shares of the biotechnologDecember 10, 2024 | marketbeat.comBNP Paribas Financial Markets Grows Position in AnaptysBio, Inc. (NASDAQ:ANAB)BNP Paribas Financial Markets lifted its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 6,009.9% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 66,109 shares of the biotechnologyDecember 7, 2024 | marketbeat.comAnaptysBio, Inc. (NASDAQ:ANAB) Shares Bought by Fmr LLCFmr LLC grew its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 15.3% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,309,175 shares of the biotechnology company's stockDecember 5, 2024 | marketbeat.comAnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by Parkman Healthcare Partners LLCParkman Healthcare Partners LLC cut its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 46.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 138,100 shares of the biotechnology company's stock after selling 11December 4, 2024 | marketbeat.comAnaptysBio downgraded to Neutral from Buy at BTIGDecember 3, 2024 | markets.businessinsider.comKey Takeaways From AnaptysBio Analyst RatingsDecember 3, 2024 | benzinga.comBTIG Downgrades AnaptysBio (ANAB)December 3, 2024 | msn.comAnaptysBio (NASDAQ:ANAB) Downgraded by BTIG Research to NeutralBTIG Research downgraded shares of AnaptysBio from a "buy" rating to a "neutral" rating in a research note on Monday.December 2, 2024 | marketbeat.com163,997 Shares in AnaptysBio, Inc. (NASDAQ:ANAB) Acquired by Walleye Capital LLCWalleye Capital LLC bought a new stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 163,997 shares of the biotechnology company's stock, valued at approximately $5,4December 2, 2024 | marketbeat.comCautious Optimism for AnaptysBio’s ANB032: Promising Preclinical Data Amid Efficacy UncertaintiesNovember 27, 2024 | markets.businessinsider.comJennison Associates LLC Makes New Investment in AnaptysBio, Inc. (NASDAQ:ANAB)Jennison Associates LLC acquired a new position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 264,889 shares of the biotechnology company's stock, valued at appNovember 23, 2024 | marketbeat.comVictory Capital Management Inc. Increases Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB)Victory Capital Management Inc. grew its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 677.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 237,250 shares ofNovember 22, 2024 | marketbeat.comAnaptysBio: An Immunology Pipeline-In-A-Pill Company Worth WatchingNovember 21, 2024 | seekingalpha.comTruist Financial Sticks to Its Hold Rating for AnaptysBio (ANAB)November 20, 2024 | markets.businessinsider.comAnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Rating of "Moderate Buy" by AnalystsShares of AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the twelve brokerages that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and ten have given a buy ratiNovember 17, 2024 | marketbeat.comBroker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging HigherNovember 16, 2024 | finance.yahoo.com Get AnaptysBio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Email Address 70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today! (Ad)Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. >> You can grab your FREE, laminated copies right here << ANAB Media Mentions By Week ANAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANAB News Sentiment▼0.200.61▲Average Medical News Sentiment ANAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANAB Articles This Week▼264▲ANAB Articles Average Week Get AnaptysBio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Wave Life Sciences News Today Mirum Pharmaceuticals News Today Akero Therapeutics News Today Amphastar Pharmaceuticals News Today Disc Medicine News Today Tarsus Pharmaceuticals News Today CG Oncology News Today Harmony Biosciences News Today Galapagos News Today Xencor News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ANAB) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AnaptysBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANAB Stock Alerts